Exploring new T cell therapies for treating acute B-lymphocytic leukemia
Investigating immunophenotype and metabolism of TCR KO donor and third-party CD19-targeted chimeric antigen receptor T cells
This study is looking at a new type of treatment for people with acute B-lymphocytic leukemia by using specially modified T cells that can better fight cancer while reducing side effects, with the hope of creating safer and more effective therapies that are ready to use right away.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10898918 on NIH RePORTER |
What this research studies
This research investigates the use of genetically modified T cells that have had their endogenous T cell receptors removed to improve their effectiveness against acute B-lymphocytic leukemia. By focusing on chimeric antigen receptors that target CD19, the study aims to enhance the ability of these T cells to eliminate cancer cells while minimizing complications such as graft-versus-host disease. The research will utilize preclinical models to assess how these modified T cells function in the body and their impact on immune recovery and potential rejection of the graft. The ultimate goal is to develop more effective and safer 'off-the-shelf' CAR T cell therapies for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute B-lymphocytic leukemia who may benefit from advanced CAR T cell therapies.
Not a fit: Patients with other types of leukemia or those who are not eligible for CAR T cell therapy may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for acute B-lymphocytic leukemia with fewer side effects.
How similar studies have performed: Other research has shown promise in using genetically modified T cells for cancer treatment, indicating that this approach could lead to significant advancements.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Smith, Melody — Stanford University
- Study coordinator: Smith, Melody
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.